Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$3.68.

  • SAB Biotherapeutics' EPS (Weighted Average and Diluted) rose 81.25% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.09, marking a year-over-year increase of 50.95%. This contributed to the annual value of -$3.68 for FY2024, which is 51.83% up from last year.
  • Per SAB Biotherapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$3.68 for FY2024, which was up 51.83% from -$7.64 recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' EPS (Weighted Average and Diluted) registered a high of $0.74 during FY2020, and its lowest value of -$7.64 during FY2023.
  • For the 3-year period, SAB Biotherapeutics' EPS (Weighted Average and Diluted) averaged around -$5.21, with its median value being -$4.31 (2022).
  • Per our database at Business Quant, SAB Biotherapeutics' EPS (Weighted Average and Diluted) crashed by 583.45% in 2022 and then spiked by 51.83% in 2024.
  • SAB Biotherapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at $0.74 in 2020, then crashed by 185.14% to -$0.63 in 2021, then slumped by 583.45% to -$4.31 in 2022, then plummeted by 77.44% to -$7.64 in 2023, then surged by 51.83% to -$3.68 in 2024.